| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Lysophospholipid acyltransferase 2, LPLAT 2, 231-, 1-acylglycerophosphate O-acyltransferase, 1-acylglycerophosphoethanolamine O-acyltransferase, 231n7, Lysophosphatidic acid acyltransferase, LPAAT, Lyso-PA acyltransferase, Lysophosphatidylethanolamine acyltransferase, LPEAT, Lyso-PE acyltransferase, Membrane-bound O-acyltransferase domain-containing protein 2, O-acyltransferase domain-containing protein 2, MBOAT2, OACT2 |
| Entrez GeneID | 129642 |
| WB Predicted band size | 59.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This MBOAT2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 198-227 amino acids from the Central region of human MBOAT2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SERPINA1抗体的3篇参考文献示例(内容为模拟概括，非真实文献)：
1. **文献名称**：*Autoantibodies to SERPINA1 in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease*
**作者**：Smith J, et al.
**摘要**：研究探讨了SERPINA1基因突变导致的α1-抗胰蛋白酶(AAT)缺乏症患者中，针对AAT蛋白的自身抗体水平与肝脏纤维化的相关性，提示抗体可能参与疾病进展。
2. **文献名称**：*Development of a Monoclonal Antibody for Specific Detection of Pathogenic SERPINA1 Variants*
**作者**：Lee H, et al.
**摘要**：开发了一种高特异性单克隆抗体，用于区分正常与突变型SERPINA1蛋白(如Z突变体)，助力临床诊断和病理机制研究。
3. **文献名称**：*SERPINA1 Antibodies as Biomarkers in Chronic Obstructive Pulmonary Disease*
**作者**：Garcia R, et al.
**摘要**：通过ELISA检测COPD患者血清中的抗SERPINA1抗体，发现其水平与肺功能下降程度显著相关，或为疾病监测提供新指标。
如需真实文献，建议通过PubMed或Google Scholar检索关键词“SERPINA1 antibody”“Alpha-1 antitrypsin autoantibody”。
The SERPINA1 gene encodes alpha-1 antitrypsin (AAT), a serine protease inhibitor primarily synthesized in the liver and released into the bloodstream. AAT plays a critical role in protecting tissues, particularly the lungs, from damage caused by neutrophil-derived enzymes like neutrophil elastase. SERPINA1 antibodies are essential tools for detecting and quantifying AAT in research and clinical settings. They are widely used in immunoassays (e.g., ELISA, Western blot, immunohistochemistry) to study AAT expression, monitor its levels in serum, or identify abnormal protein accumulation in conditions like alpha-1 antitrypsin deficiency (AATD).
AATD, caused by SERPINA1 gene mutations (e.g., Z allele), leads to misfolded AAT retention in hepatocytes, reducing circulating AAT and increasing risk of emphysema and liver disease. SERPINA1 antibodies help diagnose AATD by confirming low serum AAT or detecting mutant protein aggregates in liver biopsies. These antibodies also aid in research on AAT's broader roles, including anti-inflammatory, immunomodulatory, and antimicrobial functions, and its involvement in chronic obstructive pulmonary disease (COPD), fibrosis, and certain cancers.
Therapeutic AAT replacement or gene therapies for AATD rely on SERPINA1 antibodies for pharmacokinetic studies and treatment efficacy monitoring. Additionally, autoantibodies against AAT have been explored in autoimmune disorders, highlighting their diverse clinical relevance.
×
